Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.

Behbahani TE, Rosenthal EL, Parker WB, Sorscher EJ.

Head Neck. 2019 Jun;41(6):1979-1983. doi: 10.1002/hed.25627. Epub 2019 Jan 11. Review.

PMID:
30633420
2.

Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors.

Parker WB, Sorscher EJ.

Curr Pharm Des. 2017 Nov 8. doi: 10.2174/1381612823666171109101851. [Epub ahead of print]

3.
4.

6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases.

Hassan AE, Abou-Elkhair RA, Parker WB, Allan PW, Secrist JA 3rd.

Bioorg Chem. 2016 Apr;65:9-16. doi: 10.1016/j.bioorg.2015.12.006. Epub 2015 Dec 24.

PMID:
26745284
5.

6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V-Escherichia coli purine nucleoside phosphorylase.

Hassan AEA, Abou-Elkhair RAI, Parker WB, Allan PW, Secrist JA 3rd.

Eur J Med Chem. 2016 Jan 27;108:616-622. doi: 10.1016/j.ejmech.2015.12.029. Epub 2015 Dec 17.

PMID:
26724729
6.

Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity.

Parker WB, Waud WR, Secrist JA 3rd.

Curr Med Chem. 2015;22(34):3881-96. Review.

PMID:
26597061
7.

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.

Rosenthal EL, Chung TK, Parker WB, Allan PW, Clemons L, Lowman D, Hong J, Hunt FR, Richman J, Conry RM, Mannion K, Carroll WR, Nabell L, Sorscher EJ.

Ann Oncol. 2015 Jul;26(7):1481-7. doi: 10.1093/annonc/mdv196. Epub 2015 Apr 21.

8.

Role of methylthioadenosine/S-adenosylhomocysteine nucleosidase in Vibrio cholerae cellular communication and biofilm development.

Silva AJ, Parker WB, Allan PW, Ayala JC, Benitez JA.

Biochem Biophys Res Commun. 2015 May 22;461(1):65-9. doi: 10.1016/j.bbrc.2015.03.170. Epub 2015 Apr 4.

9.

Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4'-thio-2'-deoxycytidine and 5-aza-4'-thio-2'-deoxycytidine.

Thottassery JV, Sambandam V, Allan PW, Maddry JA, Maxuitenko YY, Tiwari K, Hollingshead M, Parker WB.

Cancer Chemother Pharmacol. 2014 Aug;74(2):291-302. doi: 10.1007/s00280-014-2503-z. Epub 2014 Jun 8.

10.

Effectiveness of disinfection therapies and promotion of osteoblast growth on osseotite and nanotite implant surfaces.

Lubin J, Hernandez MA, Drukteinis SE, Parker WB, Murray PE.

Implant Dent. 2014 Aug;23(4):426-33. doi: 10.1097/ID.0000000000000067.

PMID:
24776940
11.

Gingival margin changes in maxillary anterior sites after single immediate implant placement and provisionalization: a 5-year retrospective study of 47 patients.

Ross SB, Pette GA, Parker WB, Hardigan P.

Int J Oral Maxillofac Implants. 2014 Jan-Feb;29(1):127-34. doi: 10.11607/jomi.3124.

PMID:
24451863
12.

New insights into the synergism of nucleoside analogs with radiotherapy.

Lee MW, Parker WB, Xu B.

Radiat Oncol. 2013 Sep 26;8:223. doi: 10.1186/1748-717X-8-223. Review.

13.

Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage.

Yang C, Lee M, Hao J, Cui X, Guo X, Smal C, Bontemps F, Ma S, Liu X, Engler D, Parker WB, Xu B.

Nucleic Acids Res. 2012 Oct;40(19):9621-32. doi: 10.1093/nar/gks707. Epub 2012 Jul 31.

14.

In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.

Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB.

Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. doi: 10.1007/s00280-012-1908-9. Epub 2012 Jul 4.

15.

Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.

Waud WR, Parker WB, Gilbert KS, Secrist JA.

Nucleosides Nucleotides Nucleic Acids. 2012;31(1):14-27. doi: 10.1080/15257770.2011.637099.

PMID:
22257207
16.

Identification of Rv0535 as methylthioadenosine phosphorylase from Mycobacterium tuberculosis.

Buckoreelall K, Sun Y, Hobrath JV, Wilson L, Parker WB.

Tuberculosis (Edinb). 2012 Mar;92(2):139-47. doi: 10.1016/j.tube.2011.11.010. Epub 2012 Jan 4.

17.

Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

Hassan AE, Abou-Elkhair RA, Riordan JM, Allan PW, Parker WB, Khare R, Waud WR, Montgomery JA, Secrist JA 3rd.

Eur J Med Chem. 2012 Jan;47(1):167-74. doi: 10.1016/j.ejmech.2011.10.039. Epub 2011 Nov 4.

18.

Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.

Waud WR, Gilbert KS, Parker WB, Secrist JA.

Nucleosides Nucleotides Nucleic Acids. 2011 Nov;30(11):826-38. doi: 10.1080/15257770.2011.604662.

PMID:
22060549
19.

Gingival enlargement.

Pette GA, Siegel MA, Parker WB.

J Am Dent Assoc. 2011 Nov;142(11):1265-8. No abstract available.

PMID:
22041412
20.

Identification and characterization of two adenosine phosphorylase activities in Mycobacterium smegmatis.

Buckoreelall K, Wilson L, Parker WB.

J Bacteriol. 2011 Oct;193(20):5668-74. doi: 10.1128/JB.05394-11. Epub 2011 Aug 5.

21.

The crystal structure of Streptococcus pyogenes uridine phosphorylase reveals a distinct subfamily of nucleoside phosphorylases.

Tran TH, Christoffersen S, Allan PW, Parker WB, Piskur J, Serra I, Terreni M, Ealick SE.

Biochemistry. 2011 Aug 2;50(30):6549-58. doi: 10.1021/bi200707z. Epub 2011 Jul 8.

22.

Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

Parker WB, Allan PW, Waud WR, Hong JS, Sorscher EJ.

Cancer Gene Ther. 2011 Jun;18(6):390-8. doi: 10.1038/cgt.2011.4. Epub 2011 Mar 11.

23.

Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies.

Bertino JR, Waud WR, Parker WB, Lubin M.

Cancer Biol Ther. 2011 Apr 1;11(7):627-32. Epub 2011 Apr 1. Review.

24.

Cryopreserved amniotic membrane for modulation of periodontal soft tissue healing: a pilot study.

Velez I, Parker WB, Siegel MA, Hernandez M.

J Periodontol. 2010 Dec;81(12):1797-804. doi: 10.1902/jop.2010.100060. Epub 2010 Jul 14.

PMID:
20629549
25.

Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.

Tai CK, Wang W, Lai YH, Logg CR, Parker WB, Li YF, Hong JS, Sorscher EJ, Chen TC, Kasahara N.

Cancer Gene Ther. 2010 Sep;17(9):614-23. doi: 10.1038/cgt.2010.17. Epub 2010 May 14.

26.

Synthesis and anticancer evaluation of 4'-C-methyl-2'-fluoro arabino nucleosides.

Tiwari KN, Shortnacy-Fowler AT, Parker WB, Waud WR, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):657-77. doi: 10.1080/15257770903091946.

PMID:
20183608
27.

Regioselective metalation of 6-methylpurines: synthesis of fluoromethyl purines and related nucleosides for suicide gene therapy of cancer.

Hassan AE, Parker WB, Allan PW, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):642-56. doi: 10.1080/15257770903091938.

PMID:
20183607
28.

Structure of grouper iridovirus purine nucleoside phosphorylase.

Kang YN, Zhang Y, Allan PW, Parker WB, Ting JW, Chang CY, Ealick SE.

Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):155-62. doi: 10.1107/S0907444909048276. Epub 2010 Jan 22.

29.

Treatment planning and surgical considerations in implant therapy for patients with agenesis, oligodontia, and ectodermal dysplasia: review and case presentation.

Sclar AG, Kannikal J, Ferreira CF, Kaltman SI, Parker WB.

J Oral Maxillofac Surg. 2009 Nov;67(11 Suppl):2-12. doi: 10.1016/j.joms.2009.06.016. Review. No abstract available.

PMID:
19835745
30.

Synthesis and anti-Hantaan virus activity of N(1)-3-fluorophenyl-inosine.

Chung DH, Strouse JJ, Sun Y, Arterburn JB, Parker WB, Jonsson CB.

Antiviral Res. 2009 Jul;83(1):80-5. doi: 10.1016/j.antiviral.2009.03.007. Epub 2009 Apr 2.

31.

Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Parker WB.

Chem Rev. 2009 Jul;109(7):2880-93. doi: 10.1021/cr900028p. Review. No abstract available.

32.

Enhancement of the in vivo antitumor activity of clofarabine by 1-beta-D-[4-thio-arabinofuranosyl]-cytosine.

Parker WB, Shaddix SC, Gilbert KS, Shepherd RV, Waud WR.

Cancer Chemother Pharmacol. 2009 Jul;64(2):253-61. doi: 10.1007/s00280-008-0862-z. Epub 2008 Nov 11.

PMID:
19002461
33.

Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus.

Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, Parker WB, Smith J, Spik K, Ramanathan HN, Schmaljohn CS, Jonsson CB.

Antiviral Res. 2008 Jul;79(1):19-27. doi: 10.1016/j.antiviral.2008.02.003. Epub 2008 Mar 17.

34.

Structure-activity relationship for adenosine kinase from Mycobacterium tuberculosis II. Modifications to the ribofuranosyl moiety.

Long MC, Shaddix SC, Moukha-Chafiq O, Maddry JA, Nagy L, Parker WB.

Biochem Pharmacol. 2008 Apr 15;75(8):1588-600. doi: 10.1016/j.bcp.2008.01.007. Epub 2008 Feb 2.

35.

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.

Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R.

Cancer Res. 2007 Nov 15;67(22):10939-47.

36.

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R.

Mol Ther. 2007 Nov;15(11):1991-7. Epub 2007 Aug 21.

37.

Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.

Chung DH, Sun Y, Parker WB, Arterburn JB, Bartolucci A, Jonsson CB.

J Virol. 2007 Nov;81(21):11722-9. Epub 2007 Aug 15.

38.

Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase.

Kumarapperuma SC, Sun Y, Jeselnik M, Chung K, Parker WB, Jonsson CB, Arterburn JB.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3203-7. Epub 2007 Mar 12.

PMID:
17379518
39.

Purine metabolism in Mycobacterium tuberculosis as a target for drug development.

Parker WB, Long MC.

Curr Pharm Des. 2007;13(6):599-608. Review.

PMID:
17346177
40.

Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth.

Long MC, Allan PW, Luo MZ, Liu MC, Sartorelli AC, Parker WB.

J Antimicrob Chemother. 2007 Jan;59(1):118-21. Epub 2006 Nov 3.

PMID:
17085766
41.

Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.

Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB.

Antimicrob Agents Chemother. 2007 Jan;51(1):84-8. Epub 2006 Oct 23.

42.

Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine.

Roy AM, Tiwari KN, Parker WB, Secrist JA 3rd, Li R, Qu Z.

Mol Cancer Ther. 2006 Sep;5(9):2218-24.

44.

Overexpression, purification and crystallographic analysis of a unique adenosine kinase from Mycobacterium tuberculosis.

Wang Y, Long MC, Ranganathan S, Escuyer V, Parker WB, Li R.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Jun 1;61(Pt 6):553-7. Epub 2005 Jun 1.

46.

PNP anticancer gene therapy.

Zhang Y, Parker WB, Sorscher EJ, Ealick SE.

Curr Top Med Chem. 2005;5(13):1259-74. Review.

PMID:
16305530
47.

Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer.

Silamkoti AV, Allan PW, Hassan AE, Fowler AT, Sorscher EJ, Parker WB, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):881-5.

PMID:
16248054
49.

Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.

Parker WB, Allan PW, Ealick SE, Sorscher EJ, Hassan AE, Silamkoti AV, Fowler AT, Waud WR, Secrist JA 3rd.

Nucleosides Nucleotides Nucleic Acids. 2005;24(5-7):387-92.

PMID:
16247956
50.

Supplemental Content

Loading ...
Support Center